Financials

v3.23.1
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 2,937 $ 6,037
Restricted cash 196 295
Receivables 36 112
Inventory 106 293
Prepaid expenses and other current assets 314 480
Discontinued operations - current assets 14 12
Total current assets 3,603 7,229
Property and equipment, net 224 420
Other assets 48 48
Operating lease right-of-use asset 183 297
Total assets 4,058 7,994
Current liabilities:    
Accounts payable 695 795
Accrued clinical trials expenses 5 9
Other accrued liabilities 1,483 314
Operating lease liability, current 122 112
Deferred grant revenue 196 295
Discontinued operations - current liabilities 129 1,144
Total current liabilities 2,630 2,669
Operating lease liability, non-current 65 187
Total liabilities 2,695 2,856
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued or outstanding at December 31, 2022 and 2021.
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 15,016,295 and 9,914,158 shares issued and outstanding at December 31, 2022 and 2021, respectively. 15 10
Additional paid-in capital 387,609 381,183
Accumulated deficit (386,261) (376,055)
Total stockholders’ equity 1,363 5,138
Total liabilities and stockholders’ equity $ 4,058 $ 7,994

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL
v3.23.1
STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Total revenue $ 557 $ 1,526
Operating expenses:    
Cost of goods sold 199
Research and development 4,758 5,692
General and administrative 6,034 4,989
Total operating expenses 10,792 10,880
Loss from operations (10,235) (9,354)
Other income (expense):    
Interest income, net 53 1
Other expense, net (24) (84)
Non-cash gain on debt extinguishment 661
Other income, net 29 578
Net loss $ (10,206) $ (8,776)
Basic and diluted net loss per common share $ (0.76) $ (0.90)
Weighted average shares used in computing basic and diluted net loss per common share 13,434 9,730
License and Service [Member]    
Total revenue $ 60 $ 13
Product [Member]    
Total revenue 236
Grant [Member]    
Total revenue $ 497 $ 1,277

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL
v3.23.1
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss $ (10,206) $ (8,776)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 196 221
Non-cash interest expense 2
Non-cash gain on debt extinguishment (661)
Stock-based milestone payment 50
Stock-based compensation 947 1,505
Amortization of restricted stock 450 36
Other 2 (7)
Changes in operating assets and liabilities:    
Receivables 76 772
Inventory 187 35
Prepaid expenses and other assets 164 163
Accounts payable (751) (1,191)
Other accrued liabilities 801 (293)
Deferred revenue (99) 295
Net cash used in operating activities (8,183) (7,899)
Cash flows from investing activities:    
Purchases of furniture and equipment (23)
Net cash used in investing activities (23)
Cash flows from financing activities:    
Proceeds from equity offerings 4,980 8,841
Proceeds from the exercise of warrants 4
Net cash provided by financing activities 4,984 8,841
Net change in cash, cash equivalents and restricted cash (3,199) 919
Cash, cash equivalents and restricted cash at beginning of year 6,332 5,413
Cash, cash equivalents and restricted cash at end of year 3,133 6,332
Supplemental disclosure of cash flow information    
Right of use asset obtained in exchange for lease liability, net of amortization 149
Retirement of property and equipment 1,372
Accumulated depreciation on retired property and equipment (1,372)
Cash and cash equivalents 2,937 6,037
Restricted cash 196 295
Cash, cash equivalents and restricted cash as shown in the statements of cash flows $ 3,133 $ 6,332

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL